Membres du jury

Christophe Cans - 2017
Chef Strategic Marketing Officer • Inserm transfert

Christophe Cans

Christophe Cans, Ph.D, Chef Strategic Marketing Officer at Inserm transfert (France), the technology transfer office of Inserm, the 1st European biomedical research Institute. Initially in charge of scouting innovative projects through Inserm for several years, he is heading the department of Marketing and Industrial Partnerships, developing a customized approach for industrial partners to reinforce, create, stimulate breakthrough innovation based on the multiple assets and competence/expertise of Inserm., including entreneurship.

Scientist by formation , with a PhD in cellular and molecular biology from the University of Toulouse, Christophe directed several oncology research programs at the European Molecular Biology Laboratory (EMBL-Heidelberg) and oncology- immuno-inflammation drug discovery in biotechnology companies. He has 15 years of experience in various Biotechnology companies and technology transfert.

Marc Gitzinger - 2017
CEO and Co-founder • Bioversys

Marc Gitzinger

Marc completed his studies in Biology at the University of Freiburg (Germany) and the University of Queensland (Australia). He holds a PhD in Biotechnology from the ETH Zurich. Besides his excellent skills in molecular biology, he gained business experience as Associate Intern at McKinsey & Company and insights to intellectual property rights at the patent offices Ernest T. Freylinger SA (Luxemburg) and Joachim Stuercken GmbH (Germany). Marc is winner of the Venture Leaders 2008 award.

Olivier Guery - 2017
Senior Director of Projects, Licensing & Business Development • Servier

Olivier Guery

Olivier Guery is a MD, former resident physician of Paris Hospitals, with a training in pediatrics and cardiology. He completed a MBA at Sorbonne University and later on obtained an advanced management degree from ESSEC Business School. He initially joined Servier’s R&D to manage international clinical development of cardiovascular projects and then head a cardiovascular division, before establishing and managing the clinical development organization of Servier in Central and Eastern Europe. He then joined Serviers’s Licensing and Business Development and participated in the creation of this new activity, in parallel to the international expansion of Servier, developing a broad network of relationships and initiating collaborations with pharmaceutical and biotechnology companies worldwide in all major therapeutic areas of the company. During the recent period, he has been responsible for Servier’s in-licensing activities in the cardio-metabolic area, setting up multi-disciplinary evaluation groups within Servier, and achieving numerous licensing and research collaboration agreements, with a significant impact on the activity of the company.

Antony Lebeau - 2017
Program Officer • National Research Agency

Antony Lebeau

PhD in Neuropharmacology (University Paris Descartes) and titular of a Master’s degree in Company Management (CNAM-International Institut of Management), Antony Lebeau has successively worked as research engineer (Inserm/Research Institut of Servier), project manager (GIS Prion-Ministry of Research, Inserm Transfert), communication manager (Inserm-Tranfert and Inserm-Transfert Initiative. He joined the French National Research Agency (ANR) as project manager in the of « Health Biology » department, working on Technology Transfer programs (RIB/Biotecs ,TecSan). He currently works as program officer in the ANR department of « Investments for the future and competitiveness », working in the field of public-private partnerships. Antony Lebeau has been also expert for the European Commission and for the ERC in « Health and Biotechnology » and « Ethic and Governance » fields for the past 8 years.

Pierre Legrain - 2017
Executive Vice President Business Development • Institut Pasteur

Pierre Legrain

Dr. Pierre Legrain, PhD in Genetics, has published over 80 scientific articles and has a solid research and management background. Recently he had the responsibility of Master and PhD students at the Graduate School of Ecole Polytechnique. Until 2012, he coordinated the evaluation of public research in the life sciences at AERES. He joined the CEA (French Alternative Energies and Atomic Energy Commission) in 2003 at the Direction of Biology Department of Joliot-Curie, and later on managed the CEA Life Sciences Division. Pierre started as Laboratory Director at Institut Pasteur in 1995, where he created and managed the first start-up: Hybrigenics.

Dr Legrain’s key role at the Development Department at the Institut Pasteur is to foster the development of transversal research programs, some of which concern major human health areas, such as vaccinology, microbiology, oncology and brain science. These programs involve both Institut Pasteur Campus teams and the entire Institut Pasteur international network. In the initial stages, these programs were self-financed but they now attract new partners, from the industry and from foundations and funding agencies, in France and abroad.

Rafi Mardachti - 2017
Associate Director • Universal Medica Group

Rafi Mardachti

Rafi Mardachti is a Pharmacist (Pharm.D) from the University of Paris XI (France). He has an MBA from the Albany College of Pharmacy of Union University (USA). He is a Master of Pharmaceutical Marketing from the University of Paris XI (France). He is the winner of the National Thesis prize in 1995: Mail Order Pharmacy.
His previous positions were: Regional District Manager at MEDCO (USA), Pharmacist Manager at Marionnaud (France), Health Manager Director at Quintiles (Europe). He is the founder and CEO of Universal Medica.
Rafi Mardachti has published various articles in specialized media and teaches at various schools and specialized Master’s degrees.

Mallory Perrin-Wolff - 2017
Head of Incentive Research Programs and Partnerships Department • Institut Pasteur

Mallory Perrin-Wolff

Mallory Perrin-Wolff has joined the Institut Pasteur in Paris late 2014 as the head of the Incentive Research Programs and Partnerships Department, part of the Development Department. Her current goals and challenges are (1) to source, launch and support a series of strategic research programs by using Institut Pasteur seed funding for the early-stage and (2) to seek partnerships for further development and funding for those programs.

She was previously Director of Strategic Partnerships & Alliances at Inserm Transfert with a specific goal on Open innovation area. She has a 15-year experience in the Technology Transfer covering biomedical research and human health. She joined Inserm Transfert in 2006 where she progressively became a Business Development/Licensing executive, in charge of the Immunology-inflammation domain with a strong focus on biopharmaceuticals (therapeutic monoclonal antibodies and technology platforms). She has a broad experience of public-private partnership between the academic research and worldwide Biotech/biopharma Industry developing Open innovation deals, early-stage in-licensing, technical evaluation and alliance management.
Mallory holds a Ph.D in Immunology and Molecular pharmacology (University Paris Descartes, France) with extensive experience in oncology and endocrinology area (post-doctoral and Inserm scientific positions).

Chantal Vernis - 2017
CEO • SATTLutech

Chantal Vernis

Convaincue que le développement économique et sociétal passe par l’innovation, Chantal Vernis s’engage depuis plus de 15 ans à impulser une nouvelle dynamique dans le transfert de connaissances, compétences et résultats de la recherche publique vers les entreprises.

Après avoir travaillé près de 20 ans dans l’industrie aérospatiale, elle a rejoint le CNRS où son investissement au sein de la Direction de l’Innovation et des Relations avec les Entreprises (DIRE) a conduit à la création de 300 entreprises innovantes à même d’exploiter les technologies mises au point dans des laboratoires de recherche.

Dans l’équipe de direction de la SATT Lutech dès sa création en 2012, elle œuvre à la mise en place de sa stratégie opérationnelle ainsi qu’à la structuration et à l’essor son activité. Depuis 2014, elle en assure également la présidence et déploie une politique audacieuse en cohérence avec celle des établissements de recherche et d’enseignement supérieur actionnaires de la société.

Nader Yaghoubi - 2017
President and CEO • PathMaker Neurosystems

Nader Yaghoubi

Nader Yaghoubi, M.D., Ph.D., is President and CEO of PathMaker Neurosystems, a clinical-stage neuromodulation company with operations in France and US. He has over 16 years of experience in the creation, operations and financing of life science companies. Prior to starting PathMaker, he was President and CEO of Symbiotix Biotherapies, a pioneering microbiome company emerging from Harvard Medical School. Before these, he was the first employee at Selecta Biosciences (Nasdaq:SELB) and BIND Therapeutics (Nasdaq:BIND), nanoparticle companies emerging from MIT. Previously, he was at Zero Stage Capital, a venture capital firm where he was responsible for investing in the life sciences sector, and was also an intern at Advent International. Dr. Yaghoubi received an M.D. and Ph.D. in Molecular Pharmacology from the combined degree program at Boston University School of Medicine. His doctorate work on the development of high-throughput automated electrophysiological systems resulted in five issued US patents, received one of his University’s highest awards for dissertational research, and was the basis of a venture-backed neuroscience company. He is extensively involved in mentoring young companies, and has served/serves as a mentor, advisor and reviewer with Massachusett’s Biotechnology Council’s MassCONNECT program, Mass Life Sciences Center programs, Springboard Venture Capital Forum and numerous university business plan competitions.

 
 


Laurent Audoly - 2016
Pierre Fabre

Laurent Audoly

Coming soon

Laurent Benel - 2016
CSO and co-founder • CleveXel Pharma

Laurent Benel

Laurent is has more than 25 years of experience in Pharmaceutical R&D centered on management of teams and projects such as research programs, organizational changes and facility build-up, logistic and organization. Prior to Clevexel Pharma, he was associate director at Cephalon Development Centre. Cell biologist and pharmacologist by training, he has spent more than 18 years in discovery research at Laboratoire Lafon and Cephalon Inc. managing research programs in inflammation and oncology. Laurent holds a Ph.D. in Pharmaceutical Sciences from Paris XI University.

Julien Demaude - 2016
International Predictive Models for Evaluation, Director • L’Oréal

Julien Demaude

Dr. Julien DEMAUDE received his doctoral degree in Pharmacology on Inflammatory Bowel Disease from Université Paul Sabatier (Toulouse, France) in 2003.He then completed a MBA in Management of Innovation and Biotechnology before joining L’Oréal in 2006 as an intern in Scientific communications. In 2007, he joined L’Oreal as a Junior Scientist working on vitro biological evaluation for anti-aging actives from cell-based assays to 3D model assays. He then moved in the Department of Open Research first in France working on International Collaboration with universities and private companies on Skin Evaluation, Cosmetic and Dermo-Cosmetics. He then moved to the US in order to develop and strengthen the relations with North American Universities, start-ups, private companies and key opinion leaders from a simple consultancy agreement to strong and sharp research contracts. He was looking for new technologies, new knowledge but POC and original bioactive compounds as well. Since 2013, we came to France as the International Predictive Models for Evaluation, Director, in which he manages 25 people. The main role of his department is to develop predictive in vitro methods and models for the efficacy of our new raw materials in an “agile” way of working.
It’s also to translate and transform biological knowledge into predictive test structures to make RM as safe and efficient as possible.

Jean Derégnaucourt - 2016
Executive Vice President Business Development • Institut Pasteur

Jean Derégnaucourt

D V M, Thesis Prize Winner, Graduate in Pharmacology (Paris Medical Faculty), Post doctoral fellow at UCLA, was recently appointed Exec VP Bus Dev at Pasteur Institute after being CEO of the Medicen Paris Region Biocluster. He also is currently President, VP or Member of various Scientific or Bus Dev Committees. His previous positions were VP Project Management, then VP Chemical and Pharm Dev at Rhone Poulenc Rorer (1990-1998) and later, President of the Pierre Fabre Laboratories R&D (1998-2003). He contributed to the international development and worldwide registration of a dozen of products among them two blockbusters, Clexane and Taxotere. Very recently, FDA approved Fetzimab an antidepressor, he patented a few years ago. For a few years he also moved to an institutional position as Director of Biotechnology at the French Research Ministry (2003-2006). He also was Vice President of the Biotech Company Cellvir which he cofounded in 2008.

Antony Lebeau - 2016
Program Officer • National Research Agency

Antony Lebeau

PhD in Neuropharmacology (University Paris Descartes) and titular of a Master’s degree in Company Management (CNAM-International Institut of Management), Antony Lebeau has successively worked as research engineer (Inserm/Research Institut of Servier), project manager (GIS Prion-Ministry of Research, Inserm Transfert), communication manager (Inserm-Tranfert and Inserm-Transfert Initiative. He joined the French National Research Agency (ANR) as project manager in the of « Health Biology » department, working on Technology Transfer programs (RIB/Biotecs ,TecSan). He currently works as program officer in the ANR department of « Investments for the future and competitiveness », working in the field of public-private partnerships. Antony Lebeau has been also expert for the European Commission and for the ERC in « Health and Biotechnology » and « Ethic and Governance » fields for the past 8 years.

Pierre Legrain - 2016
Executive Vice President Business Development • Institut Pasteur

Pierre Legrain

Dr. Pierre Legrain, PhD in Genetics, has published over 80 scientific articles and has a solid research and management background. Recently he had the responsibility of Master and PhD students at the Graduate School of Ecole Polytechnique. Until 2012, he coordinated the evaluation of public research in the life sciences at AERES. He joined the CEA (French Alternative Energies and Atomic Energy Commission) in 2003 at the Direction of Biology Department of Joliot-Curie, and later on managed the CEA Life Sciences Division. Pierre started as Laboratory Director at Institut Pasteur in 1995, where he created and managed the first start-up: Hybrigenics.

Dr Legrain’s key role at the newly created Academic Development and Grant office Department at the Institut Pasteur is to foster the development of transversal research programs, some of which concern major human health areas, such as vaccinology, microbiology, oncology and brain science. These programs will involve both Institute Pasteur Campus teams and the entire Institute Pasteur international network. In the initial stages, these programs may be self-financed but they should attract new funding partners in subsequent phases.

Andreas Lymberis - 2016
Research Program Officer • European Commission

Andreas Lymberis

Andreas Lymberis is a physicist, post-graduated with a Ph.D. in biomedical engineering and sciences (1990, Paris, France). He worked for more than 20 years as researcher/engineer and R&D manager in biomedical technology and health telematics. In 1999 he joined the European Commission (Brussels, Belgium) as a scientific officer in eHealth where he initiated R&D activities on “smart wearable health systems and biomedical clothing”. Since 2004 he is senior research program officer first in microsystems and recently in electronic components and systems. He is member of the EC team in charge of the drafting and monitoring the EU research, development & innovation programs for ICT and coordinates two thematic areas: « micro-nano-bio systems (MNBS) » and « e-textile & wearable » systems. His activities in supporting innovation consist of identification of innovation opportunities within projects and beneficiaries, coordination and knowledge sharing as well as assistance to potential innovators towards fulfilling their potential in the market place. He is Senior IEEE Member and chaired the IEEE-EMBS Technical Committee on Wearable Biomedical Sensors and Systems (2004-2007). He published over 60 articles in journals, conference proceedings & books and he is editor of 2 books on wearable and mobile health systems.

Rafi Mardachti - 2016
Associate Director • Universal Medica Group

Rafi Mardachti

Rafi Mardachti is a Pharmacist (Pharm.D) from the University of Paris XI (France). He has an MBA from the Albany College of Pharmacy of Union University (USA). He is a Master of Pharmaceutical Marketing from the University of Paris XI (France). He is the winner of the National Thesis prize in 1995: Mail Order Pharmacy.
His previous positions were: Regional District Manager at MEDCO (USA), Pharmacist Manager at Marionnaud (France), Health Manager Director at Quintiles (Europe). He is the founder and CEO of Universal Medica.
Rafi Mardachti has published various articles in specialized media and teaches at various schools and specialized Master’s degrees.

Ola Winqvist - 2016
Professor, Senior Consultant • Karolinska Institute

Ola Winqvist

Immunologist with extensive experience of managing academic research and entrepreneurial experience from founding several start up companies in Life Science.
Education:

  • M. D., University of Uppsala 1991
  • Ph. D., University of Uppsala 1994
  • Post-Doc at Scripps Research Institute, La Jolla, CA, USA 1995-1998
  • Associate Professor Experimental Medicine 1999
  • Professor Clinical Immunol 2011

Professionnal experience:
I did my PhD on Addison’s disease and my post doc at Scripps research Institute working with antigen processing, presentation and peripheral tolerance mechanisms. I’m now heading a group of 12 persons working with immune mediated disease. I´m presently Professor of cellular immunotherapy and senior consultant heading cellular immunology at the Karolinska University Hospital. Since 2010 I’m the Director of the Karolinska FOCIS center of excellence allowing and since 2013 I’m the director of The Swedish Immunology Society.

 
 

Rodica Ababii - 2015
Medical Project Leader • GSK Pharma

Rodica Ababii

Rodica Ababii is nephrologist and holds an MD degree and post-graduate University Diploma in Nephrology from Moldova Faculty of Medicine. She worked in public hospital for several years before joining pharmaceutical industry. She joined GSK in 1998, and held increasingly responsible positions in Medical (Pharmacovigilance and Clinical Research) as well as in Marketing and Sales, including General Management of one of the Eastern Europe countries.
Since 2007 she is Medical Manager in Early phase research, New domains and Academic alliances team of GSK France, creating links between GSK R&D groups and French Public research teams.

Zeina Antoun - 2015
Clinical Research Director • GlaxoSmithKline

Zeina Antoun

Zeina Antoun holds an MD degree from the American University of Beyrouth and has an American Board certification in Internal Medicine, and a University Diploma in Infectious Diseases. Between 1994 and 1998, she worked at Bichat, Claude-Bernard Hospital as a full-time clinician in Infectious Diseases and HIV. In 1998, she joined GlaxoSmithKline France, Clinical research unit in Virology, and was then appointed in 2004 as Director, Clinical research in Virology, Therapeutic Vaccines, Oncology and Respiratory diseases. In 2007, Zeina Antoun created a new department dedicated to Early phase research, New domains and Academic alliances, creating many links between GSK R&D groups and French Public research teams. Zeina Antoun is a member of several external working groups at LEEM, ARIIS, Investment funds and other boards. She is also co-author on many publications.

Olivier Guery - 2015
Senior Director of Projects, Licensing & Business Development • Servier

Olivier Guery

Olivier Guery is a MD, former resident physician of Paris Hospitals, with a training in pediatrics and cardiology. He completed a MBA at Sorbonne University and later on obtained an advanced management degree from ESSEC Business School. He initially joined Servier’s R&D to manage international clinical development of cardiovascular projects and then head a cardiovascular division, before establishing and managing the clinical development organization of Servier in Central and Eastern Europe. He then joined Serviers’s Licensing and Business Development and participated in the creation of this new activity, in parallel to the international expansion of Servier, developing a broad network of relationships and initiating collaborations with pharmaceutical and biotechnology companies worldwide in all major therapeutic areas of the company. During the recent period, he has been responsible for Servier’s in-licensing activities in the cardio-metabolic area, setting up multi-disciplinary evaluation groups within Servier, and achieving numerous licensing and research collaboration agreements, with a significant impact on the activity of the company.

Olivier Guth - 2015
Head of Innovation, Evaluation and Project coordination • Mayoly-Spindler

Olivier Guth

Olivier Guth is Doctor in Pharmacy from the University of Paris V and holds a MBA from ESGCI – Paris – (Ecole Supérieure de Gestion et de Commerce International).
He has nearly 17 years experiences in the Pharmaceutical industry during which he held different positions in R&D Project management, Business Development and Production.
Olivier GUTH joined MAYOLY-SPINDLER in 2004. He was first Head of Business Development for the CMO part of the Group and then joined the Scientific Direction as the Head of Pharmaceutical Development to manage several R&D programs. Currently Head of Innovation, Evaluation and Project coordination, he is now in charge of the Research and the Evaluation of new Innovated products and R&D partnerships.
Before joining MAYOLY-SPINDLER, he worked for ETHYPHARM and DIAGNOSTICA STAGO as Production Director.
MAYOLY-SPINDLER is a privately owned french company which focuses on Gastroenterology and Dermo-cosmetics fields.

Frédéric Scaerou - 2015
Director Scientific Affairs Oncology • Ipsen

Frédéric Scaërou

Frédéric Scaërou is Director Scientific Affairs at Ipsen Innovation where he is responsible for identifying, implementing and monitoring key Public/Private scientific partnerships in Oncology which aim to sustain Ipsen R&D innovation.
Before joining Ipsen, Frédéric held various management positions in biopharmaceutical companies, academia and the not-for-profit sector. He worked in discovery research in France (Cytomics Pharmaceuticals) and in the UK (Cyclacel Ltd), in technology transfer (Institut Curie) and was, more recently, the director of research operations and science funding for the largest french cancer charity.
He holds a PhD in Biology and Genetics from the University of Paris VI.